228: A surprise success in Alzheimer's and how FDA history seeded modern controversy
Lecanemab, a new Alzheimer's treatment from partners Biogen and Eisai, succeeded in a pivotal clinical trial, and we explain the surprising development and its sweeping implications. Then, oncologist Mikkael Sekeres joins us to talk about his new book, which is a history of the FDA and an insider\u2019s look at one of the agency\u2019s most contentious drug approval hearings.